Suven Life Sciences Stock Screener | Share Price & Fundamental Analysis
SUVEN
Healthcare Technology
Screen Suven Life Sciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹161.92
▼
-2.89 (-1.75%)
Share Price BSE
₹161.80
▼
-3.20 (-1.94%)
Market Cap
₹3,780.39 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
13.36
EPS (TTM)
₹-7.37
Dividend Yield
-
Debt to Equity
-
52W High
₹233.36
52W Low
₹161.92
Operating Margin
-8671.00%
Profit Margin
-1540.00%
Revenue (TTM)
₹5.00
EBITDA
₹-76.00
Net Income
₹-77.00
Total Assets
₹135.00
Total Equity
₹110.00
Suven Life Sciences Share Price History - Stock Screener Chart
Screen SUVEN historical share price movements with interactive charts. Analyze price trends and patterns.
Suven Life Sciences Company Profile - Fundamental Screener
Screen Suven Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUVEN shares.
Sector
Healthcare
Industry
Healthcare Technology
Sub-Sector
Healthcare Technology
Segment
E
ISIN
INE495B01038
Suven Life Sciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen SUVEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 135 | 285 | 389 | 108 | 128 | 182 | 303 | 919 | 816 | 752 |
| Current Assets | 76 | 257 | 252 | 67 | 103 | 66 | 281 | 570 | 492 | 428 |
| Fixed Assets | 60 | 28 | 37 | 38 | 21 | 25 | 22 | 308 | 306 | 305 |
| Liabilities | ||||||||||
| Total Liabilities | 135 | 285 | 389 | 108 | 128 | 182 | 303 | 919 | 816 | 752 |
| Current Liabilities | 2 | 1 | 3 | 4 | 5 | 12 | 25 | 30 | 30 | 46 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 110 | 270 | 375 | 96 | 108 | 143 | 239 | 767 | 667 | 595 |
| Share Capital | 22 | 22 | 22 | 15 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 88 | 248 | 354 | 82 | 58 | 131 | 226 | 755 | 654 | 583 |
Screen SUVEN income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 3 | 3 | 3 | 7 | 5 | 7 | 9 | 16 | 9 | 8 | 5 | 5 | 10 | 4 |
| Expenses | 81 | 53 | 45 | 41 | 55 | 32 | 33 | 49 | 27 | 32 | 34 | 55 | 26 | 25 | 24 |
| EBITDA | -76 | -50 | -43 | -38 | -48 | -27 | -26 | -40 | -11 | -22 | -26 | -49 | -22 | -15 | -20 |
| Operating Profit % | -8671.00% | -2714.00% | -2981.00% | -2435.00% | -2032.00% | -3023.00% | -1267.00% | -1885.00% | -768.00% | -737.00% | -1208.00% | -1720.00% | -494.00% | -595.00% | -467.00% |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -77 | -52 | -44 | -39 | -50 | -28 | -28 | -42 | -13 | -24 | -28 | -51 | -23 | -16 | -21 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -77 | -52 | -44 | -39 | -50 | -28 | -27 | -42 | -13 | -24 | -28 | -51 | -23 | -16 | -21 |
| EPS | -3.48 | -2.36 | -2.02 | -1.79 | -2.27 | -1.29 | -1.22 | -1.92 | -0.58 | -1.10 | -1.17 | -2.90 | -1.51 | -1.12 | -1.63 |
Suven Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SUVEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -154 | -116 | -116 | -128 | -96 | -135 | -53 | 70 | 109 | 68 |
| Investing Activities | 155 | 94 | -248 | -22 | 56 | 146 | 30 | -1 | -311 | -39 |
| Financing Activities | -1 | -1 | 396 | 146 | 35 | 3 | 5 | -52 | -30 | -68 |
| Net Cash Flow | 0 | -22 | 32 | -4 | -5 | 14 | -18 | 17 | -232 | -39 |
Screen SUVEN shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jul | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 67.36% | 67.43% | 70.27% | 70.27% | 70.27% | 70.27% | 70.27% | 69.57% |
| FII Holding | 1.18% | 0.56% | 0.59% | 0.25% | 0.34% | 0.34% | 0.45% | 0.46% |
| DII Holding | 3.39% | 3.41% | 0.02% | 0.01% | 1.06% | 1.05% | 1.17% | 1.17% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.25% | 22.24% | 23.17% | 24.04% | 22.31% | 22.15% | 22.66% | 22.29% |
| Other Holding | 5.82% | 6.37% | 5.95% | 5.44% | 6.04% | 6.19% | 5.46% | 6.51% |
| Shareholder Count | 64,921 | 65,574 | 66,159 | 64,603 | 63,537 | 63,975 | 66,116 | 68,959 |
Suven Life Sciences Dividend Screener - Share Yield Analysis
Screen SUVEN dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.50 | 7.61% |
| 2018-March | ₹1.50 | 0.57% |
| 2017-March | ₹1.00 | 12.85% |
Suven Life Sciences Index Membership - Market Screener Classification
Screen SUVEN by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Suven Life Sciences Market Events Screener - Corporate Actions
Screen SUVEN market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -5.22% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 53.37% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -13.24% |
| 2025-06-05 | 2025-06-05 | Extraordinary General Meeting | NA | 53.37% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 16.60% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -8.29% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -7.61% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 26.09% |
| 2022-10-17 | 2022-10-18 | Rights | 1:2 | 4.83% |
Suven Life Sciences Competitors Screener - Peer Comparison
Screen SUVEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Syngene International | 26,314 | 55.90 | 3,714 | 3.77% | 496 | 51.46 |
| Indegene | 12,600 | 28.01 | 2,947 | 10.53% | 407 | 42.94 |
| Suven Life Sciences | 3,780 | -17.74 | 18 | -46.34% | -161 | 39.99 |
| Vimta Labs | 2,694 | 43.62 | 322 | 0.22% | 41 | 44.90 |
| Take Solutions | 602 | 12.37 | 10 | 126.67% | 1 | 87.87 |
| Bilcare | 185 | -4.17 | 807 | 4.78% | -56 | 43.28 |
| Jeevan Scientific Technology | 103 | -22.71 | 48 | 17.87% | 0 | 62.49 |
| Adeshwar Meditex | 26 | 33.09 | 84 | 5.00% | 2 | 21.16 |
| Vanta Bioscience | 17 | -1.26 | 2 | -78.57% | -13 | 20.40 |
Suven Life Sciences Company Announcements - News Screener
Screen SUVEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Closure of Trading Window | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Un-Audited Standalone And Consolidated Financial Results For Quarter And Half-Year Ended 30Th September 2025 | View |
| 2025-11-03 | Board Meeting Intimation for To Consider And Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half-Year Ended September 30 2025 And Related Matters | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-08-22 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-08-22 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-08-13 | Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On August 13 2025 | View |
| 2025-08-05 | Board Meeting Intimation for Consider & Approve Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30 2025 And Related Matters | View |
| 2025-07-30 | Business Responsibility and Sustainability Reporting (BRSR) | View |
| 2025-07-30 | Notice Of 36Th Annual General Meeting (AGM) Of The Company | View |
| 2025-07-30 | Reg. 34 (1) Annual Report. | View |
| 2025-07-24 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-07-16 | Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Suven Life Sciences Limited Held On Wednesday July 16 2025 - Allotment Of 9186490 Equity Shares Of The Company On Preferential Basis Upon Conversion 9186490 Fully Paid Warrants | View |